Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2014

Conditions
Melanoma
Interventions
DRUG

AZD6244

oral capsules, 75mg twice daily

DRUG

Dacarbazine

1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle

DRUG

Placebo

Placebo

Trial Locations (38)

Unknown

Research Site, Aurora

Research Site, Boston

Research Site, Belo Horizonte

Research Site, Ijuí

Research Site, Porto Alegre

Research Site, São Paulo

Research Site, Brno

Research Site, Nový Jičín

Research Site, Prague

Research Site, Lille

Research Site, Marseille

Research Site, Villejuif

Research Site, Berlin

Research Site, Essen

Research Site, Hanover

Research Site, Kiel

Research Site, Tübingen

Research Site, Budapest

Research Site, Győr

Research Site, Székesfehérvár

Research Site, Amsterdam

Research Site, Nijmegen

Research Site, Oslo

Research Site, Barcelona

Research Site, Houston

Research Site, Málaga

Research Site, Palma de Mallorca

Research Site, Gothenburg

Research Site, Malmo

Research Site, Stockholm

Research Site, Zurich

Research Site, Cambridge

Research Site, Chelmsford

Research Site, London

Research Site, Manchester

Research Site, Newcastle upon Tyne

Research Site, Oxford

Research Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY